AAV9 VRs and their reported functional roles. Refer to http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393551
| VR | AAV9 aa | Reported functional role(s) | References |
|---|---|---|---|
| VR-I | 262–269 | Unknown in AAV9 | |
| VR-II | 327–332 | DE loop at the 5-fold channel; possible role in genome packaging | |
| VR-III | 382–386 | Unknown in AAV9 | |
| VR-IV | 452–460 | aa 456–476, liver transduction efficiency determinant; aa 456-568, delayed blood clearance phenotype | 37, 60 |
| VR-V | 488–505 | aa 489–545 LamR receptor binding footprint; aa 498, 503, and 504, effect on liver- and muscle-specific transduction; aa 456-568, delayed-blood-clearance phenotype | 2, 37, 60 |
| VR-VI | 527–539 | aa 489–545, LamR receptor binding footprint; aa 456-568, delayed-blood-clearance phenotype | 2, 37 |
| VR-VII | 545–558 | aa 550–568, liver transduction efficiency determinant; aa 456-568, delayed blood clearance phenotype | 37, 60 |
| VR-VIII | 581–593 | aa 591–621, LamR receptor binding footprint: aa 582, 590, 592, transduction | 2, 60 |
| VR-IX | 704–714 | aa 699–735, determinant of heart tropism; determinant of improved melanoma tropism in chimeric virus, chimeric-1829; aa 706, mutants exhibited altered tropism | 43 |